HK Stock Market Move | BOAN BIOTECH (06955) rose nearly 5%, Shandong LUYE PHARMA plans to further transfer the company's H shares to Luye Geneora Holding.

BOAN BIOTECH (06955) rose nearly 5%, rising by 4.23% as of the time of writing, to 9.12 Hong Kong dollars, with a turnover of 358 million Hong Kong dollars. In terms of news, on January 21, BOAN BIOTECH announced that the board of directors had been informed by the controlling shareholder LUYE PHARMA Group that, in accordance with the terms of the subscription agreement related to the convertible preference shares, it is planned for LUYE PHARMA's wholly-owned subsidiary Shandong LUYE PHARMA Co., Ltd. to further transfer 38.5 million H shares of Luye Geneora Holding Limited in the market on January 22, 2026, as part of the proposed transfer. It is understood that LUYE PHARMA previously integrated BOAN BIOTECH into its system by acquiring 98% of its shares, obtaining its antibody drug pipeline, technology platform, and production assets. Through its ownership of Shandong LUYE PHARMA Co., Ltd., LUYE PHARMA has become the core controlling entity. As of 2025, Shandong LUYE PHARMA Co., Ltd. holds 70.81% of BOAN BIOTECH's shares. BOAN BIOTECH is a key carrier for LUYE PHARMA's upgrade from traditional small molecules to biopharmaceuticals, helping to build a dual-line research and development system of "chemical drugs + biological drugs".